SAN DIEGO--(BUSINESS WIRE)--March 06, 2023--
Revelation Biosciences Inc. (
NASDAQ: REVB) (the "Company" or "Revelation"), a life sciences company that is focused on the development of immunologic-based therapies for the prevention and treatment of disease, announced today that its Chief Executive Officer James Rolke will participate in a fireside chat at the 35th Annual Roth Conference scheduled for March 12-14, 2023 to be held at The Ritz Carlton, Laguna Niguel in Dana Point, California.
Details regarding Revelation fireside chat are as follows:
35th Annual Roth Conference Presentation Details
Date: Tuesday, March 14, 2023 Time: 12:30 p.m. Pacific Time Location: Healthcare - Salon 5 @ The Ritz Carlton, Laguna Niguel Webcast: REVB Webcast Link
A live webcast of the presentation will also be available in the Investor Relations section of Revelation's website at
https://www.revbiosciences.com. A replay of the presentation will be available on Revelation's website for 30 days following the event.
Mr. Rolke will be available for one-on-one meetings throughout the conference in person and virtually.
About Revelation Biosciences Inc.
Revelation Biosciences, Inc. is a life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. Revelation has multiple product candidates in development that are based on the well-established biology of phosphorylated hexaacyl disaccharide (PHAD) and its effect on the innate immune system. REVTx--100 is being developed as a prevention and treatment of infection. REVTx--200 is being developed as an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx--300 is being developed as a potential therapy for the treatment of acute and chronic organ disease including AKI, CKD, myocarditis, and NASH. REVTx--99b is being developed as a treatment for food allergies. REVDx--501 is being developed as a rapid diagnostic that can be used to detect IP-10 as a surrogate biomarker for any type of respiratory infection, eliminating the need for specialized instrumentation.
For more information on Revelation, please visit www.RevBiosciences.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230306005202/en/
CONTACT: Sandra Vedrick
Vice President, Investor Relations & Human Resources
Revelation Biosciences Inc.
Email: svedrick@revbiosciences.com
and
Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: czygmont@revbiosciences.com
SOURCE: Revelation Biosciences Inc. Copyright Business Wire 2023
(END)